Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(3-4):495–500. doi: 10.1038/sj.bjc.6690077

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

D C McMillan 1, S J Wigmore 2, K C H Fearon 2, P O'Gorman 1, C E Wright 2, C S McArdle 1
PMCID: PMC2362415  PMID: 10027319

Abstract

The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4–6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P < 0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P < 0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted. © 1999 Cancer Research Campaign

Keywords: prospective randomized study, gastrointestinal cancer, weight loss, megestrol acetate, ibuprofen, acute phase response

Full Text

The Full Text of this article is available as a PDF (92.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson N. K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N. J., Filiberti A., Flechtner H., Fleishman S. B., de Haes J. C. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376. doi: 10.1093/jnci/85.5.365. [DOI] [PubMed] [Google Scholar]
  2. Falconer J. S., Fearon K. C., Plester C. E., Ross J. A., Carter D. C. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994 Apr;219(4):325–331. doi: 10.1097/00000658-199404000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fearon K. C., Falconer J. S., Slater C., McMillan D. C., Ross J. A., Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg. 1998 Feb;227(2):249–254. doi: 10.1097/00000658-199802000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Feliu J., González-Barón M., Berrocal A., Ordóez A., Barón-Saura J. M. Treatment of cancer anorexia with megestrol acetate: which is the optimal dose? J Natl Cancer Inst. 1991 Mar 20;83(6):449–450. doi: 10.1093/jnci/83.6.449. [DOI] [PubMed] [Google Scholar]
  5. Göransson J., Jonsson S., Lasson A. Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol. 1996 Dec;22(6):607–617. doi: 10.1016/s0748-7983(96)92398-7. [DOI] [PubMed] [Google Scholar]
  6. Hannan W. J., Cowen S. J., Plester C. E., Fearon K. C., deBeau A. Comparison of bio-impedance spectroscopy and multi-frequency bio-impedance analysis for the assessment of extracellular and total body water in surgical patients. Clin Sci (Lond) 1995 Dec;89(6):651–658. doi: 10.1042/cs0890651. [DOI] [PubMed] [Google Scholar]
  7. Inagaki J., Rodriguez V., Bodey G. P. Proceedings: Causes of death in cancer patients. Cancer. 1974 Feb;33(2):568–573. doi: 10.1002/1097-0142(197402)33:2<568::aid-cncr2820330236>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  8. Kern K. A., Norton J. A. Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):286–298. doi: 10.1177/0148607188012003286. [DOI] [PubMed] [Google Scholar]
  9. Loprinzi C. L., Ellison N. M., Schaid D. J., Krook J. E., Athmann L. M., Dose A. M., Mailliard J. A., Johnson P. S., Ebbert L. P., Geeraerts L. H. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990 Jul 4;82(13):1127–1132. doi: 10.1093/jnci/82.13.1127. [DOI] [PubMed] [Google Scholar]
  10. McMillan D. C., Graham A. F., Smith J., Wotherspoon H. A., Fearon K. C., McArdle C. S. Interleukin-6, neutrophilia and the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1994 Apr;20(2):151–154. [PubMed] [Google Scholar]
  11. McMillan D. C., Leen E., Smith J., Sturgeon C., Preston T., Cooke T. G., McArdle C. S. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995 Oct;21(5):531–534. doi: 10.1016/s0748-7983(95)97157-2. [DOI] [PubMed] [Google Scholar]
  12. McMillan D. C., O'Gorman P., Fearon K. C., McArdle C. S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer. 1997;76(6):788–790. doi: 10.1038/bjc.1997.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McMillan D. C., Preston T., Watson W. S., Simpson J. M., Fearon K. C., Shenkin A., Burns H. J., McArdle C. S. Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer. Br J Surg. 1994 Jul;81(7):1011–1014. doi: 10.1002/bjs.1800810727. [DOI] [PubMed] [Google Scholar]
  14. Mor V., Laliberte L., Morris J. N., Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984 May 1;53(9):2002–2007. doi: 10.1002/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  15. Ovesen L., Hannibal J., Mortensen E. L. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer. 1993;19(2):159–167. doi: 10.1080/01635589309514246. [DOI] [PubMed] [Google Scholar]
  16. Preston T., Fearon K. C., McMillan D. C., Winstanley F. P., Slater C., Shenkin A., Carter D. C. Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg. 1995 Feb;82(2):229–234. doi: 10.1002/bjs.1800820233. [DOI] [PubMed] [Google Scholar]
  17. Raben A., Tagliabue A., Astrup A. The reproducibility of subjective appetite scores. Br J Nutr. 1995 Apr;73(4):517–530. doi: 10.1079/bjn19950056. [DOI] [PubMed] [Google Scholar]
  18. Scott H. R., McMillan D. C., Crilly A., McArdle C. S., Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer. 1996 Jun;73(12):1560–1562. doi: 10.1038/bjc.1996.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tchekmedyian N. S., Hickman M., Siau J., Greco F. A., Keller J., Browder H., Aisner J. Megestrol acetate in cancer anorexia and weight loss. Cancer. 1992 Mar 1;69(5):1268–1274. doi: 10.1002/cncr.2820690532. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES